Wyndham Hotels & Resorts (NYSE:WH) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker11Good morning, everyone. Welcome to the Wyndham Hotels & Resorts fourth quarter and full year 2025 earnings conference call. At this time, all participants have been placed on a listen-only mode, and the floor will be open for your questions following the presentation. If you would like to ask a question at that time, please press star one on your telephone. If at any point your question has been answered, you may ...

Gold Fields (NYSE:GFI) H2 2025 Earnings call February 19, 2026 08:00 AM ET Speaker5Good afternoon, good morning, and good evening for those that have joined the presentation of our financial year 2025 results. And on behalf of the team at Gold Fields, I'm really pleased to deliver a very, very strong set of results for the group. Going into the presentation, I will run through a short presentation that'll be shared between myself and Alex, and then we will spend some time at the back end addressing question ...

Financial Data and Key Metrics Changes - Insmed reported a strong performance in 2025, with revenue guidance for BRINSUPRI of at least $1 billion in 2026, reflecting confidence in market access and early launch performance [5][6][25] - The company anticipates total revenue in 2026 to be more than double that of 2025, indicating a significant growth trajectory [6][25] - As of the end of 2025, Insmed had approximately $1.4 billion in cash, cash equivalents, and marketable securities, positioning the company well for future investments [29][31] Business Line Data and Key Metrics Changes - BRINSUPRI launched in the U.S. with net revenue of $144.6 million in its first full quarter, exceeding expectations [7][20] - ARIKAYCE showed strong growth, particularly in Japan with a 40% increase compared to 2024, contributing significantly to global revenues [21][25] - The company is pursuing additional DPP1 inhibitors for respiratory diseases, indicating a strategy to expand its product portfolio [35] Market Data and Key Metrics Changes - The total addressable market for BRINSUPRI in the U.S. is estimated at 500,000 diagnosed patients with non-CF bronchiectasis, with significant potential for expansion as more patients are identified [8][10] - The company is actively working to identify additional patients with undiagnosed bronchiectasis among those with COPD and asthma, which could significantly increase the patient base for BRINSUPRI [12][13] Company Strategy and Development Direction - Insmed aims to accelerate the U.S. launch of BRINSUPRI while continuing to grow ARIKAYCE, focusing on expanding its clinical pipeline in respiratory, inflammation, immunology, and neurology [4][5] - The company is committed to pursuing first or best-in-class therapies within its target therapeutic areas, indicating a proactive approach to pipeline development [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity without needing to raise additional capital, although they may seek capital for strategic opportunities [6][31] - The positive early feedback from physicians and patients regarding BRINSUPRI is expected to drive further prescribing behavior, enhancing the launch's momentum [17][66] Other Important Information - The gross-to-net guidance for BRINSUPRI in 2026 is expected to be in the mid-20s to low 30s percentage range, reflecting favorable payer contracting dynamics [27][28] - The company is evaluating several business development opportunities to support pipeline expansion and value creation [6][31] Q&A Session Summary Question: Plans to develop other DPP1 inhibitors - Insmed intends to bring other DPP1s forward, including INS1033 for rheumatoid arthritis and inflammatory bowel disease, and is also advancing DPP1s for respiratory conditions [35] Question: Guidance for BRINSUPRI and patient behavior - Management is seeing metrics at or above targets, contributing to confidence in achieving at least $1 billion in revenue for BRINSUPRI [39] Question: Trends in scrip data and interest in business development - Management noted strong initial performance and is open to pursuing first or best-in-class compounds for business development [42][45] Question: Depth of prescribing and physician behavior - Physicians are initially prescribing BRINSUPRI to one or two patients, with expectations that positive experiences will lead to increased prescribing [66] Question: Ex-U.S. contribution to BRINSUPRI guidance - Ex-U.S. contributions for BRINSUPRI in 2026 are expected to be very small, with a focus on U.S. market dynamics [58]

Six Flags Entertainment (NYSE:FUN) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker6Good morning, everyone. My name is Ellie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Six Flags Entertainment Corporation 2025 fourth quarter earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's prepared remarks, there will be a question and answer session. If you would like to ask a question during this time, ...

Bandwidth (NasdaqGS:BAND) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker6Good day, and welcome to the Bandwidth Inc. fourth quarter and full year 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then 1 on your telephone keypad, and to withdraw your que ...

Wayfair (NYSE:W) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker5Hello, everyone. Thank you for joining us, and welcome to the Wayfair Q4 2025 earnings release and conference call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. To withdraw your question, please press star one again. I will now hand the call over to Ryan Barney, Investor Relations. Please go ahead.Speaker6Good morning ...

CRH (NYSE:CRH) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker8Good day, and welcome to the CRH fourth quarter and full year 2025 results presentation. My name is Krista, and I will be your operator today. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question, please press Star and then the number one on your telephone keypad at any time. If you would like to withdraw your ...

Financial Data and Key Metrics Changes - Revenue for the fourth quarter increased by 4.9% in constant currency, with e-commerce growth at 24% [4][14] - Adjusted operating income grew by 10.5%, outpacing sales growth [4][14] - For the full year, total revenue exceeded $700 billion for the first time, with a 5% increase in constant currency [14] - Adjusted operating income for the full year grew by 5.4%, despite a 300 basis point headwind from increased claims expenses [14][23] Business Line Data and Key Metrics Changes - Walmart U.S. comp sales rose by 4.6%, with e-commerce sales growing by 27% [14][15] - International segment operating income increased by over 26%, driven by improved e-commerce economics [15] - Advertising income globally increased by 37%, with Walmart Connect in the U.S. up by 41% [16][35] - Membership income grew by over 15%, reflecting strength in Sam's Club in China and the U.S. [16] Market Data and Key Metrics Changes - E-commerce sales in China grew by 28%, representing more than 50% of the sales mix in that market [15] - Fast delivery services in the U.S. saw a growth of over 60% year-over-year [9][15] - The majority of share gains in the U.S. came from households earning over $100,000, while lower-income households are managing spending carefully [5][6] Company Strategy and Development Direction - The company is focused on an omnichannel strategy, leveraging technology and automation to enhance customer experience and delivery speed [4][9] - Investments in AI and technology are aimed at improving inventory management and customer engagement through tools like Sparky [10][11] - The strategy includes capital allocation based on return on investment, with a focus on maintaining a strong value proposition for customers [7][20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's momentum and the ability to navigate complex operating conditions [13][41] - The outlook for the upcoming fiscal year includes sales growth expectations of 3.5% to 4.5% and operating income growth of 6% to 8% [21][22] - Management remains cautious about potential economic headwinds but is optimistic about the company's ability to outperform guidance [41][42] Other Important Information - The company authorized a $30 billion share repurchase program, its largest to date, reflecting confidence in cash flow generation [23] - Capital expenditure levels for FY 2027 are expected to be approximately 3.5% of sales, with a focus on supply chain automation and store remodels [24] Q&A Session Summary Question: On agentic commerce and its impact on customer traffic and advertising - Management highlighted that agentic commerce is part of the omnichannel strategy, enhancing customer intent understanding and driving higher average order values [28][29][32] Question: Regarding unexpected costs and outlook for the year - Management noted a measured approach to guidance, considering potential economic indicators while maintaining flexibility [37][41] Question: On disinflation and its impact on pricing - Management indicated that inflation trends are expected to remain stable, with some pressures from legislation affecting drug prices [44][45] Question: About e-commerce profitability and competition - Management emphasized the importance of maintaining share momentum through effective inventory management and leveraging technology [84]

EPAM Systems (NYSE:EPAM) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker10Good day, everyone. My name is Kahealani, and I'll be your conference operator today. At this time, I would like to welcome you to EPAM's fourth quarter and full year 2025 earnings release conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, and if you have joined via t ...

LKQ (NasdaqGS:LKQ) Q4 2025 Earnings call February 19, 2026 08:00 AM ET Speaker6Hello, everyone, and thank you for joining the LKQ Corporation's fourth quarter and full year 2025 earnings conference call. My name is Lucy, and I'll be coordinating your call today. During the presentation, you can register a question by pressing Star followed by one on your telephone keypad. If you change your mind, please press Star followed by two. It is now my pleasure to hand over to your host, Joe Boutross, Vice President ...